Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/52065
Type
ArticleCopyright
Open access
Collections
- IOC - Artigos de Periódicos [12488]
Metadata
Show full item record
SHOULD COVID-19 BE BRANDED TO VIRAL THROMBOTIC FEVER ?
SARS-CoV-2
Endotélio
SARS CoV Mpro
Inflamação
Coagulação
Hipercoagulabilidade
Trombose
COVID-19
SARS-CoV-2
SARS CoV Mpro
Inflammation
Coagulation
Hypercoagulability
Thrombosis
Author
Affilliation
Hospital Pró-Cardíaco, Américas Serviços Médicos. United-Health Group. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz.Instituto Oswaldo Cruz. Laboratório de Imunologia Clínica. Rio de Janeiro, RJ, Brasil / Centro Universitário Arthur Sá Earp Neto. Faculdade de Medicina de Petrópolis. Petrópolis, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Patologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Inflamação. Rio de Janeiro, RJ, Brasil.
Instituto Nacional de Câncer. Rio de Janeiro, RJ, Brasil.
Políticas de Saúde do United-Health Group. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Proteômica Estrutural e Computacional. Curitiba, PR, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Virologia Comparada e Ambiental. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz.Instituto Oswaldo Cruz. Laboratório de Imunologia Clínica. Rio de Janeiro, RJ, Brasil / Centro Universitário Arthur Sá Earp Neto. Faculdade de Medicina de Petrópolis. Petrópolis, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Patologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Inflamação. Rio de Janeiro, RJ, Brasil.
Instituto Nacional de Câncer. Rio de Janeiro, RJ, Brasil.
Políticas de Saúde do United-Health Group. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Proteômica Estrutural e Computacional. Curitiba, PR, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Virologia Comparada e Ambiental. Rio de Janeiro, RJ, Brasil.
Abstract
Coronaviruses can cause a diverse array of clinical manifestations, from fever with symptoms of the common cold to highly
lethal severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS). SARS-CoV-2, the coronavirus
discovered in Hubei province, China, at the end of 2019, became known worldwide for causing coronavirus disease 2019
(COVID-19). Over one year’s time period, the scientific community has produced a large bulk of knowledge about this disease
and countless reports about its immune-pathological aspects. This knowledge, including data obtained in postmortem studies,
points unequivocally to a hypercoagulability state. However, the name COVID-19 tells us very little about the true meaning of
the disease. Our proposal is more comprehensive; it intends to frame COVID-19 in more clinical terminology, making an analogy
to viral haemorrhagic fever (VHF). Thus, we found irrefutable evidence in the current literature that COVID-19 is the first viral
disease that can be branded as a viral thrombotic fever. This manuscript points out that SARS-CoV-2 goes far beyond pneumonia
or SARS. COVID-19 infections promote remarkable interactions among the endothelium, coagulation, and immune response,
building up a background capable of promoting a “thrombotic storm,” much more than a “cytokine storm.” The importance of
a viral protease called main protease (Mpro) is highlighted as a critical component for its replication in the host cell. A deeper
analysis of this protease and its importance on the coagulation system is also discussed for the first time, mainly because of its
similarity with the thrombin and factor Xa molecules, as recently pointed out by structural comparison crystallographic structures.
Keywords in Portuguese
COVID-19SARS-CoV-2
Endotélio
SARS CoV Mpro
Inflamação
Coagulação
Hipercoagulabilidade
Trombose
Keywords
EndotheliumCOVID-19
SARS-CoV-2
SARS CoV Mpro
Inflammation
Coagulation
Hypercoagulability
Thrombosis
Share